Pfizer Ibrance Hopes Dashed In Early-Stage Breast Cancer

 
• By Joseph Haas
  
New York, July 19, 2016: Corporate lettering on the exterior of the Pfizer headquarters in Manhattan.
With a second failed study, Pfizer's hopes for Ibrance in early breast cancer crash

More from Clinical Trials

More from R&D